Cancer Research · global
Dismantling Cancer Cells’ Antioxidant Defenses: Phase I Trial of Mesothelioma Drug Shows Signs of Disease Control
RSO-021 targets PRX3 in mitochondria, exposing tumors to their own accumulated oxidative stress. In a small trial, 6 of 9 evaluable patients had disease control at 12 weeks, but whether it can extend survival remains to be confirmed in controlled studies.
Patients with pleural mesothelioma, which is closely associated with asbestos exposure, often face limited options when the disease recurs after treatment. Researchers are seeking a way forward by targeting the defense systems cancer cells depend on to survive: blocking an enzyme that clears oxidants so that the stress tumors generate themselves becomes a vulnerability. The first human trial of the experimental drug RSO-021 has shown preliminary signs of disease control.
The study was published in *Nature Communications* on July 14, 2026. Mesothelioma cells generate large amounts of reactive oxygen species and must rely on antioxidant systems to maintain balance. Among these, peroxiredoxin 3 (PRX3) in mitochondria removes hydrogen peroxide. RSO-021 is a clinical formulation of the natural antibiotic thiostrepton, developed by RS Oncology based on research at the University of Vermont in the United States. It is designed to disable this defense and allow oxidative damage to accumulate.
A key question in moving from the laboratory to patients is whether the drug actually acts on its target. The team first confirmed in cell and animal models that removing PRX3 weakened mesothelioma growth, and observed drug-induced apoptosis in patient-derived tumor tissue. The human trial also found evidence of PRX3 crosslinking by the drug in pleural fluid samples from two patients, supporting the possibility that this mechanism can occur in the human body.
The phase I trial, called MITOPE, treated 15 people, including 12 with pleural mesothelioma, all of whom had experienced disease progression after standard treatment. Patients received weekly intrapleural administration through an indwelling catheter, delivering the drug directly into the space between the lung and chest wall. According to UK NIHR trial information, the overall study uses an open-label, nonrandomized phase I/II design, primarily assessing safety, tolerability and an appropriate dose, while antitumor activity remains an exploratory assessment.
The efficacy figures need to be read alongside their denominators: among the 9 patients evaluable at 12 weeks, 6 achieved disease control, approximately 67%. Only 1 had a partial response; the other 5 had stable disease. Median progression-free survival among evaluable mesothelioma patients was 18 weeks. In the overall survival analysis of the 12 mesothelioma patients, the median had not been reached at the 80-week data cutoff. Given the small number of patients and the absence of a concurrent control group, these results are not yet sufficient to demonstrate that the drug is superior to existing treatments or can extend life.
The safety findings also indicated dose limits. None of the 7 patients receiving 90 milligrams experienced dose-limiting toxicity, but severe inflammatory reactions, rapid breathing or difficulty breathing occurred in the 120- and 180-milligram groups. This supports further exploration of local drug delivery, while also reminding researchers that tolerability findings from a phase I trial cannot be directly extrapolated to long-term safety.
Further research must clarify which tumors are most likely to benefit and how drug resistance develops. Preclinical experiments suggest that the transporter protein SLC7A11 may be involved in resistance to thiostrepton, but it has not yet become a clinically validated marker for treatment selection. A July announcement from the University of Vermont stated that the phase II trial had been completed, with results expected later in 2026; this paper still reports phase I data. Researcher Brian Cunniff also serves as chief scientific officer of RS Oncology. Larger, controlled studies will be key to determining the value of this therapeutic approach.